Roche, a Swiss pharmaceutical company, announced a $50 billion investment in the U.S. over the next five years, creating over 12,000 jobs. This investment, spurred by potential new tariffs on imported pharmaceuticals, will fund new R&D sites, expand manufacturing facilities in several states, and build a new large-scale manufacturing center for weight-loss medications. The move follows similar large investments by other pharmaceutical companies, aiming to strengthen their U.S. presence. Roche expects to export more medicines from the U.S. than it imports once the investments are complete.

Prepared by Christopher Adams and reviewed by editorial team.